Kymera Therapeutics, Inc. 2025 Q4 - Results - Earnings Call Presentation

Kymera Therapeutics reported a Q4 2025 earnings per share loss of $0.98, missing analyst estimates by $0.21, reflecting ongoing financial challenges in its biotech operations. Quarterly revenue plunged 61.18% year-over-year to $2.87 million, falling $12.18 million short of projections, signaling weakened commercial performance or partnership setbacks. The earnings call slide deck, released February 2026, accompanied the results, likely detailing strategic pivots or pipeline updates amid the financial downturn. No breakthrough announcements were highlighted, suggesting the company is still in a pre-revenue or R&D-intensive phase with limited near-term monetization. Investors may scrutinize cost-cutting measures or clinical milestones after consecutive misses, raising questions about Kymera’s path to profitability.